HEART SENTRY - By lexingtonBioSciences.com

Lexington Bio Sciences new :Heart Sentry"!

Wednesday, August 29, 2018

Retire Fund Web Domain Package

The Retire Fund Web Domain package

has just been increased from a package of 5 RetireFund Domains to 

6 Web Addresses for 1 Price!!!

The Domains being offered as a package are:


To buy this package go to:



These two Domains were sold for these prices previously:

RETIRE.COM  $2,000,000
FUND.COM    $10,000,000

NOW!  Your company can own all six of our 
RETIRE FUND Domains for one price!!!

SEE:  Marketplace.Epik.com/RETIRE.FUND

RetireFund - What are your clients doing?
                        "AFTER WORK"!

Note: The sale and Escrow will be handled by reliable third party broker Epik.com

Sunday, August 5, 2018

RetireFund - 5 Premium Web Addresses on sale as a package! Retire.Fund

These five premium, RetireFund Web Domains are being sold as a package!

Meet the asking price and you're company will own all five of these Fund Domains for your portfolio of Retirement Funds.


This package is available until September 15th 2018 

To Buy this package or to place a bid on Retire.Fund, please go to:


To buy only one of these names click on the Domain of your choice!

Should an individual Domain be sold before Sept 15th 2018, the remaining Domains will be sold individually!

Note: The following Domains were previously sold for the price indicated:
sold for $2,000,00

sold for $10,000,000

Now you can own this entire package of

domains for low six figures if you act now!

B O N U S!!!

ON August 29th 2018, we added a 6th Domain to this package and extended the deadline to September 15, 2018!


Now you can own all six of these valuable Web Domains for one price for your RetireFund Business!!!

Go to:

DomainNames.Money/Retire.Fund - click

Wednesday, July 25, 2018

Lexington Biosciences Receives HeartSentry USPTO Patent Approval!

VANCOUVER, BC – July 25, 2018) – Lexington Biosciences, Inc. (Toronto TSE: LNB) (OTCQB: LXGTF) is pleased to announce the issuance of U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry device.

“Today’s news is a big deal for Lexington,” says Company CEO, Eric Willis. “The US Patent Office and our legal team did an extraordinary job in arriving at this approval so quickly. The fact that all key claims were reviewed and approved without significant amendment speaks volumes to the veracity of our research and the clearly defined parameters of the operating methodology. We also have numerous patents pending on individual aspects of the science, both domestically and overseas, but this particular patent approval should pave the way for subsequent approvals in other global jurisdictions.”

HeartSentry was designed by Lexington’s lead researcher, Chief
Scientific Advisor Jonathan S. Maltz, Ph.D., as a diagnostic device that provides a new approach to non-invasive measurement and monitoring of cardiovascular health. 

 The device assesses the function of a patient’s vascular endothelium, the vital innermost lining of the cardiovascular system. The Company designed HeartSentry to be highly portable, accurate, quick, and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners, and ultimately for patients as a first-line evaluation of cardiovascular health.

The public is invited to follow us on Facebook, Twitter and LinkedIn. To receive our newsletter and news alerts direct to your inbox, you can signup at any time on any of the signup opportunities or “contact” page of our website.

To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead.

About Lexington Biosciences, Inc. (CSE: LNB / OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of the cardiovascular system.  Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician.

HeartSentry core technology was developed at the Lawrence Berkeley National Laboratory over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.  Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.

On Behalf of the Board,
“Eric Willis”
Eric Willis
CEO  Director

Lexington Biosciences, Inc.
+1 (800) 320-2640

Thursday, July 5, 2018

The Donald's lack of vision in negotiations puts the USA at a distinct disadvantage!

By David Honig

I'm going to get a little wonky and write about Donald Trump and negotiations. For those who don't know, I'm an adjunct professor at Indiana University - Robert H. McKinney School of Law and I teach negotiations. 

Trump, as most of us know, is the credited author of "The Art of the Deal," a book that was actually ghost written by a man named Tony Schwartz, who was given access to Trump and wrote based upon his observations. If you've read The Art of the Deal, or if you've followed Trump lately, you'll know, even if you didn't know the label, that he sees all deal making as what we call

 "distributive bargaining."

Distributive bargaining always has a winner and a loser. It happens when there is a fixed quantity of something and two sides are fighting over how it gets distributed. Think of it as a pie and you're fighting over who gets how many pieces. 

In Trump's world, the bargaining was for a building, or for construction work, or subcontractors. He perceives a successful bargain as one in which there is a winner and a loser, so if he pays less than the seller wants, he wins. The more he saves the more he wins.

The other type of bargaining is called integrative bargaining.

 In integrative bargaining the two sides don't have a complete conflict of interest, and it is possible to reach mutually beneficial agreements. Think of it, not a single pie to be divided by two hungry people, but as a baker and a caterer negotiating over how many pies will be baked at what prices, and the nature of their ongoing relationship after this one gig is over.

The problem with Trump is that he sees only distributive bargaining in an international world that requires integrative bargaining. 

 He can raise tariffs, but so can other countries. He can't demand they not respond. There is no defined end to the negotiation and there is no simple winner and loser. There are always more pies to be baked. 
Further, negotiations aren't binary. China's choices aren't (a) buy soybeans from US farmers, or (b) don't buy soybeans. They can also (c) buy soybeans from Russia, or Argentina, or Brazil, or Canada, etc. That completely strips the distributive bargainer of his power to win or lose, to control the negotiation.

One of the risks of distributive bargaining is bad will. In a one-time distributive bargain, e.g. negotiating with the cabinet maker in your casino about whether you're going to pay his whole bill or demand a discount, you don't have to worry about your ongoing credibility or the next deal. If you do that to the cabinet maker, you can bet he won't agree to do the cabinets in your next casino, and you're going to have to find another cabinet maker.
 There isn't another Canada.

So when you approach international negotiation, in a world as complex as ours, with integrated economies and multiple buyers and sellers, you simply must approach them through integrative bargaining. If you attempt distributive bargaining, success is impossible. And we see that already.

Trump has raised tariffs on China. China responded, in addition to
raising tariffs on US goods, by dropping all its soybean orders from the US and buying them from Russia. The effect is not only to cause tremendous harm to US farmers, but also to increase Russian revenue, making Russia less susceptible to sanctions and boycotts, increasing its economic and political power in the world, and reducing ours. 

Trump saw steel and aluminum and thought it would be an easy win, BECAUSE HE SAW ONLY STEEL AND ALUMINUM - HE SEES EVERY NEGOTIATION AS DISTRIBUTIVE. China saw it as integrative, and integrated Russia and its soybean purchase orders into a far more complex negotiation ecosystem.

Trump has the same weakness politically. For every winner there must be a loser. And that's just not how politics works, not over the long run.

For people who study negotiations, this is incredibly basic stuff, negotiations 101, definitions you learn before you even start talking about styles and tactics. And here's another huge problem for us.

Trump is utterly convinced that his experience in a closely held real estate company has prepared him to run a nation, and therefore he rejects the advice of people who spent entire careers studying the nuances of international negotiations and diplomacy. But the leaders on the other side of the table have not eschewed expertise, they have embraced it. And that means they look at Trump and, given his very limited tool chest and his blindly distributive understanding of negotiation, they know exactly what he is going to do and exactly how to respond to it. 

From a professional negotiation point of view, Trump isn't even bringing checkers to a chess match. He's bringing a quarter that he insists on flipping for heads or tails, while everybody else is studying the chess board to decide whether its better to open with Najdorf or Grünfeld.

Thursday, June 21, 2018

Trade Wars never end well - History shows us why!

History's Not on the Market's Side in a Trade War - Article at Bloomberg


The first shots of a global trade war were fired on Friday as U.S. President Donald Trump announced a 25 percent levy on $50 billion of imports from China. The tariffs focus on “industrially significant technology,” and intend to hurt China for alleged theft of intellectual property rights. China responded within hours with a detailed list of imports from the U.S. valued at $50 billion that it would impose a similar 25 percent tax on...


Trumps Trade War makes no sense....

Washington Post

A Trade War with China damages both sides...

New York Times Article... 

Markets begin to take Trade War Seriously...

Wall Street Journal 

Trump's Trade War will hurt Economy....

Why Donald Trump's trade wars are so risky now...